Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Oncology
Aplastic Anemia Treatment in Turkey
Aplastic anaemia is a rare and serious blood condition in which the bone marrow fails to generate sufficient new blood cells. It affects both young people and older adults, who typically see a physician for persistent exhaustion, frequent infections, or unexplainable bruising and bleeding. Tailored haematological care and supportive options depend on an immediate specialist assessment. Compare hospitals in Turkey that treat Aplastic Anemia and get a free review of your medical records.
- Price from
- Price on request
- Clinics
- 2
- Treated with
- 1
Verified surgeons for Aplastic Anemia
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
About Aplastic Anemia
Aplastic anaemia is a rare and serious blood condition in which the bone marrow fails to generate sufficient new blood cells. It affects both young people and older adults, who typically see a physician for persistent exhaustion, frequent infections, or unexplainable bruising and bleeding. Tailored haematological care and supportive options depend on an immediate specialist assessment.
Specialty: Oncology
Treatment options
Depending on the stage and your medical history, doctors may recommend:
Best Clinics for Aplastic Anemia Treatment in Turkey
Frequently asked questions
The cost of treating Aplastic Anemia depends on the diagnosis and the treatment chosen. Doctors first review your medical records — free of charge — and you then receive an itemised quote.
Options may include Comprehensive Diagnosis of Aplastic Anemia. Your doctor chooses the approach after reviewing your tests and scans.
Aplastic Anemia is treated by Oncology specialists. 2 clinics in Turkey on our platform offer this treatment.
What is Aplastic Anaemia and What are Its Symptoms?
Aplastic anaemia is a rare haematological disorder characterised by the inability of the bone marrow to generate adequate blood cells. Inside healthy bone marrow, haematopoietic stem cells divide and mature into red blood cells, white blood cells, and platelets. In aplastic anaemia, immune-mediated damage suppresses these progenitor cells, causing pancytopenia across all three peripheral cell lineages.
Haematologists categorise the condition by severity—moderate, severe, or very severe—based on bone marrow cellularity and peripheral blood counts. Typical symptoms include:
- Anaemia (erythrocyte deficiency): Persistent fatigue, pale complexion, breathlessness during ordinary exertion, dizziness, headaches, and rapid pulse.
- Thrombocytopenia (platelet deficiency): Spontaneous mucosal bleeding, unexplained bruising, petechiae (pinpoint red spots beneath the skin), nosebleeds, bleeding gums, and prolonged bleeding from cuts.
- Neutropenia (leukocyte deficiency): Recurrent bacterial or fungal infections, unexplained fevers, chills, and painful mouth ulcers.
Diagnostic Assessments for Aplastic Anaemia in Turkey
An exact diagnosis differentiates aplastic anaemia from hypoplastic myelodysplastic syndromes, acute leukaemias, and paroxysmal nocturnal haemoglobinuria (PNH). Hospitals in Turkey conduct thorough evaluations alongside comprehensive diagnostic investigations.
Key hospital diagnostics include:
- Bone marrow aspiration and trephine biopsy: The definitive diagnostic benchmark. The biopsy evaluates cellularity, revealing marked hypocellularity—often below 25 percent—with marrow spaces replaced by fat cells, without leukemic blasts or fibrosis.
- Full blood count and reticulocyte count: Establishes neutrophil, platelet, and haemoglobin levels. A reduced reticulocyte count confirms impaired red cell production.
- High-sensitivity flow cytometry: Examines peripheral blood for CD55 and CD59 deficiencies to detect co-existing PNH clones.
- Cytogenetic and molecular testing: Karyotyping and FISH rule out clonal chromosomal abnormalities. In children evaluated in paediatric haematology units, chromosomal breakage tests exclude Fanconi anaemia.
- Viral screening: Tests for hepatitis viruses, cytomegalovirus, Epstein-Barr virus, and parvovirus B19.
Patients should bring original biopsy reports, pathology slides, recent blood counts, transfusion histories, and HLA tissue typing records for themselves and siblings.
Treatment Options for Aplastic Anaemia
Treatment strategy depends on disease severity, patient age, general health, and donor availability. Within hospital oncology and haematology units, therapeutic pathways are decided after complete clinical reassessment.
| Option | Typically used when | Things to know |
|---|---|---|
| Allogeneic Stem Cell Transplant | First-line option for children and young adults with severe or very severe aplastic anaemia who have a matched sibling donor. | Replaces defective stem cells with healthy donor cells, supported by regenerative cellular therapies infrastructure. Requires pre-transplant conditioning, protective isolation, and monitoring for graft-versus-host disease. |
| Immunosuppressive Therapy (IST) | Patients lacking an HLA-matched sibling donor, older individuals, or those unsuitable for intensive transplantation. | Combines antithymocyte globulin (ATG) with cyclosporine, often augmented with eltrombopag to stimulate marrow recovery over three to six months. |
| Supportive Haematological Care | Essential for all patients during initial presentation, active therapy, or while awaiting response. | Includes irradiated, leukocyte-depleted blood and platelet transfusions, prophylactic antimicrobial medications, and iron chelation therapy for secondary iron overload. |
Therapeutic outcomes depend on individual baseline health, and treatment plans are determined solely by the treating haematologist after direct evaluation.
Planning Your Medical Journey to Turkey
Undergoing haematological care abroad demands rigorous coordination:
- Pre-travel case review: Turkish haematology teams review marrow biopsies, cytogenetics, and blood counts remotely before departure to confirm treatment eligibility.
- Anticipated length of stay: Patients receiving immunosuppressive therapy generally stay two to four weeks for intravenous ATG infusions and monitoring for serum sickness. Those undergoing allogeneic stem cell transplantation require two to four months for conditioning, engraftment, and close outpatient surveillance.
- Post-treatment transition and rehabilitation: Coordinated haematological rehabilitation supports physical reconditioning. Before travelling home, patients receive detailed medical summaries for their home doctors, outlining cyclosporine target levels, infection precautions, and transfusion thresholds.
When Travel is Not Advisable and Urgent Safety Warnings
Aplastic anaemia can deteriorate into acute medical crises. Commercial flights introduce clinical risks due to low cabin pressure, infection exposure, and reduced oxygen levels, which can cause severe hypoxia or bleeding in cytopenic patients.
Postpone travel and seek urgent local emergency care if you experience:
- Febrile neutropenia: A temperature of 38.0°C or higher with low white counts requires broad-spectrum intravenous antibiotics within sixty minutes.
- Active bleeding: Spontaneous gum bleeding, nosebleeds, blood in stools or urine, or expanding hematomas. Flight is unsafe when platelet counts are critically low due to haemorrhage risks.
- Severe symptomatic anaemia: Chest pain, severe breathlessness at rest, or dizziness requiring urgent transfusion before travel.
- Acute infections: Chills, persistent cough, or spreading skin redness.
Always obtain written clearance from your local haematologist before travelling internationally.
Frequently asked questions
Most common anaemias, such as iron deficiency anaemia, involve insufficient red blood cells or haemoglobin while bone marrow function remains intact. In contrast, aplastic anaemia is a bone marrow failure syndrome. The marrow stops producing not only red blood cells but also white blood cells and platelets. This causes pancytopenia and exposes patients to risks of infection and spontaneous haemorrhage alongside standard fatigue.
Suitability for allogeneic stem cell transplantation depends on the patient's age, overall physical fitness, disease severity, and the availability of a compatible donor. It is typically the preferred initial therapy for children and young adults with severe aplastic anaemia who have a fully matched sibling donor. For older patients or those lacking a matched sibling, immunosuppressive therapy is generally considered the primary medical approach.
Immunosuppressive therapy with antithymocyte globulin and cyclosporine does not yield immediate improvements. The bone marrow requires time to recover stem cell function. Initial haematological response is typically evaluated between three and six months after treatment initiation. During this waiting period, patients require supportive care, including regular blood count monitoring, protective infection precautions, and irradiated blood or platelet transfusions to maintain safe circulating levels.
Patients must obtain formal written clearance from their treating haematologist before flying. Adequate platelet and haemoglobin levels must be verified shortly before departure, with transfusions administered if counts fall below safe aviation thresholds. During travel, patients should wear a well-fitted protective mask, practice diligent hand hygiene to avoid infections, stay hydrated, and carry emergency contact details and medical documentation describing their current medications and blood targets.
Yes, relapses can occur following initial response, particularly after immunosuppressive therapy when cyclosporine dosages are tapered or discontinued. A proportion of patients may experience secondary clonal evolution, such as paroxysmal nocturnal haemoglobinuria or myelodysplastic syndrome. Consequently, long-term haematological surveillance is essential. Regular blood counts and periodic bone marrow reviews allow doctors to detect any decline early and adjust immunosuppression or consider alternative therapies.